Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX)‘s stock had its “sector perform” rating reiterated by research analysts at Royal Bank of Canada in a research note issued to investors on Thursday. They presently have a $18.00 target price on the specialty pharmaceutical company’s stock, down from their prior target price of $21.00. Royal Bank of Canada’s price target suggests a potential upside of 102.70% from the stock’s previous close.
A number of other equities analysts also recently commented on the stock. Canaccord Genuity set a $12.00 target price on shares of Valeant Pharmaceuticals Intl and gave the company a “hold” rating in a research note on Tuesday, March 14th. Wells Fargo & Co reissued an “underperform” rating and issued a $10.00 target price (down previously from $11.00) on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, March 14th. They noted that the move was a valuation call. BMO Capital Markets cut their target price on shares of Valeant Pharmaceuticals Intl from $19.00 to $15.00 and set a “market perform” rating on the stock in a research note on Tuesday, March 14th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 target price (down previously from $17.00) on shares of Valeant Pharmaceuticals Intl in a research note on Saturday, March 11th. Finally, Deutsche Bank AG cut their target price on shares of Valeant Pharmaceuticals Intl from $20.00 to $19.00 and set a “hold” rating on the stock in a research note on Tuesday, March 7th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and six have assigned a buy rating to the company. Valeant Pharmaceuticals Intl has an average rating of “Hold” and a consensus price target of $24.68.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded down 1.55% during trading on Thursday, reaching $8.88. The company had a trading volume of 12,321,701 shares. Valeant Pharmaceuticals Intl has a 52 week low of $8.86 and a 52 week high of $38.50. The stock’s 50-day moving average price is $10.73 and its 200-day moving average price is $15.45. The company’s market capitalization is $3.09 billion. Valeant Pharmaceuticals Intl also saw some unusual options trading activity on Tuesday. Investors acquired 1,451 put options on the company. This represents an increase of approximately 123% compared to the average volume of 652 put options.
Valeant Pharmaceuticals Intl (NYSE:VRX) last issued its earnings results on Tuesday, February 28th. The specialty pharmaceutical company reported $1.26 EPS for the quarter, beating the Zacks’ consensus estimate of $1.20 by $0.06. Valeant Pharmaceuticals Intl had a negative net margin of 22.17% and a positive return on equity of 43.81%. The business had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.34 billion. During the same quarter last year, the firm posted $1.55 EPS. The business’s revenue for the quarter was down 12.9% compared to the same quarter last year. On average, equities analysts expect that Valeant Pharmaceuticals Intl will post $3.89 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/04/20/valeant-pharmaceuticals-intl-inc-vrx-given-sector-perform-rating-at-royal-bank-of-canada-updated-updated.html.
In other Valeant Pharmaceuticals Intl news, Director Pershing Square Capital Manage sold 18,114,432 shares of the business’s stock in a transaction dated Monday, March 13th. The shares were sold at an average price of $11.00, for a total transaction of $199,258,752.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Schutter Richard U. De bought 10,000 shares of Valeant Pharmaceuticals Intl stock in a transaction on Wednesday, March 15th. The shares were purchased at an average cost of $10.80 per share, with a total value of $108,000.00. Following the completion of the purchase, the director now directly owns 25,190 shares in the company, valued at $272,052. The disclosure for this purchase can be found here. Insiders bought a total of 3,034,000 shares of company stock valued at $32,825,280 over the last ninety days. Company insiders own 16.37% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. LeJeune Puetz Investment Counsel LLC purchased a new position in Valeant Pharmaceuticals Intl during the fourth quarter worth about $123,000. Kistler Tiffany Companies LLC raised its position in Valeant Pharmaceuticals Intl by 95.5% in the third quarter. Kistler Tiffany Companies LLC now owns 5,567 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 2,719 shares during the last quarter. Cambridge Advisors Inc. raised its position in Valeant Pharmaceuticals Intl by 0.6% in the first quarter. Cambridge Advisors Inc. now owns 12,650 shares of the specialty pharmaceutical company’s stock worth $140,000 after buying an additional 75 shares during the last quarter. US Bancorp DE raised its position in Valeant Pharmaceuticals Intl by 141.0% in the third quarter. US Bancorp DE now owns 5,745 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 3,361 shares during the last quarter. Finally, Frontier Wealth Management LLC purchased a new position in Valeant Pharmaceuticals Intl during the fourth quarter worth about $149,000. 64.34% of the stock is owned by hedge funds and other institutional investors.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.